RemeGen Co (FRA:REG) Other Long Term Assets: €17.4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:REG RemeGen Co Ltd FRA:REG
51 GF Score
Price €9.51
GF Value €15.52
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is RemeGen Co Other Long Term Assets?

RemeGen Co FRA:REG +13.97% 51 Other Long Term Assets is €17.4 Mil as of Dec. 2025. GuruFocus rates FRA:REG with a GF Score™ of 51/100 and a GF Value™ of €15.52 (Possible Value Trap). The stock has 6 warning signs investors should review.

RemeGen Co's other long-term assets for the quarter that ended in Dec. 2025 was €17.4 Mil.

RemeGen Co's quarterly other long-term assets increased from Jun. 2025 (€13.7 Mil) to Sep. 2025 (€23.5 Mil) but then stayed the same from Sep. 2025 (€23.5 Mil) to Dec. 2025 (€17.4 Mil).

RemeGen Co's annual other long-term assets declined from Dec. 2023 (€14.5 Mil) to Dec. 2024 (€11.4 Mil) but then increased from Dec. 2024 (€11.4 Mil) to Dec. 2025 (€17.4 Mil).

RemeGen Co Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Other Long Term Assets Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial 9.65 11.66 14.52 11.42 17.42

RemeGen Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.48 11.42 13.69 23.48 17.42
FRA:REG
51GF Score
RemeGen Co Ltd FRA:REG
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of €17.4 Mil mean?
RemeGen Co (FRA:REG) has a Other Long Term Assets of €17.4 Mil as of Dec. 2025. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on RemeGen Co and its competitors.
Is RemeGen Co's Other Long Term Assets too high?
RemeGen Co's current Other Long Term Assets is €17.4 Mil. Overall, RemeGen Co has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Other Long Term Assets compare to VRTX and REGN?
RemeGen Co's Other Long Term Assets of €17.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on RemeGen Co and its competitors. RemeGen Co's current Other Long Term Assets is €17.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €15.52, compared to a current price of €9.51 — trading 38.7% below its estimated fair value. The current Other Long Term Assets is €17.4 Mil. RemeGen Co's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Other Long Term Assets is €17.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (FRA:REG) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of €9.51 is trading 38.7% below its estimated GF Value™ of €15.52. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for FRA:REG:

  • Other Long Term Assets: €17.4 Mil
  • GF Value™: €15.52 vs. price of €9.51 (38.7% below fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
51GF Score

Get the complete analysis for FRA:REG

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.51
Price
€15.52
GF Value